title: Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia.
abstract: Otherwise clinically immune women in areas endemic for malaria are highly susceptible to Plasmodium falciparum malaria during their first pregnancy. Pregnancy-associated malaria (PAM) is characterized by placental accumulation of infected erythrocytes that adhere to chondroitin sulfate A (CSA). Susceptibility to PAM decreases with increasing parity, apparently due to acquisition of antibodies directed against the variant surface antigens (VSAs) that mediate the adhesion to CSA (VSA(CSA)). This study found that levels of VSA(CSA)-specific antibodies depend on endemicity, that anti-VSA(CSA) IgG is acquired during gestation week 20, and that plasma levels of the antibodies decline during the postpartum period. There is evidence that VSA(CSA)-specific antibodies are linked to placental infection and that high antibody levels contribute to the control of placental infection by inhibiting parasite adhesion to CSA. Data suggest that VSA(CSA) is a target for vaccination against PAM.
authors.affiliation: Centre for Medical Parasitology, Copenhagen University Hospital (Rigshospitalet) and Institute for Medical Microbiology and Immunology, University of Copenhagen, 2200 Copenhagen N, Denmark. tscmp@rh.dk
authors.forename: T
authors.initials: T
authors.lastname: Staalsoe
authors.forename: R
authors.initials: R
authors.lastname: Megnekou
authors.forename: N
authors.initials: N
authors.lastname: Fievét
authors.forename: C H
authors.initials: CH
authors.lastname: Ricke
authors.forename: H D
authors.initials: HD
authors.lastname: Zornig
authors.forename: R
authors.initials: R
authors.lastname: Leke
authors.forename: D W
authors.initials: DW
authors.lastname: Taylor
authors.forename: P
authors.initials: P
authors.lastname: Deloron
authors.forename: L
authors.initials: L
authors.lastname: Hviid
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology*; D000962:Antimalarials / Q000627:therapeutic use; D002448:Cell Adhesion; D002738:Chloroquine / Q000627:therapeutic use; D002809:Chondroitin Sulfates / Q000378:metabolism; D004912:Erythrocytes / Q000469:parasitology* / Q000502:physiology; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000276:immunology* / Q000469:parasitology; D018512:Parasitemia / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control; D010922:Placenta Diseases / Q000276:immunology* / Q000469:parasitology / Q000517:prevention & control; D010963:Plasmodium falciparum / Q000276:immunology*; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000276:immunology* / Q000469:parasitology
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000962:Antimalarials; D002738:Chloroquine; D002809:Chondroitin Sulfates